Tolerability of integrase inhibitors in a real-life setting

Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice

(2016) Mark G.J. de Boer et al.   AIDS

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients

(2016) C Hoffmann et al.   HIV MEDICINE

Discontinuation of Initial Antiretroviral Therapy in Clinical Practice

(2016) Antonio Di Biagio et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2016) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Pathophysiology of Insomnia

(2015) Jessica C. Levenson et al.   CHEST

Emerging concepts on the use of antiretroviral therapy in older adults living with HIV infection

(2015) Alan Winston et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Antiretroviral Treatment Efficacy and Safety in Older HIV-Infected Adults

(2015) Jacqueline Jourjy et al.   PHARMACOTHERAPY

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

(2014) Bonaventura Clotet et al.   LANCET

Single-tablet regimens in HIV: does it really make a difference?

(2013) Isabel Aldir et al.   CURRENT MEDICAL RESEARCH AND OPINION

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

(2013) Sharon L. Walmsley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study

(2012) P. Monteiro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

(2012) Paul E Sax et al.   LANCET

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

(2012) Edwin DeJesus et al.   LANCET

Tolerability of HIV integrase inhibitors

(2012) Frederick J. Lee et al.   Current Opinion in HIV and AIDS

Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study

(2011) B. Hasse et al.   CLINICAL INFECTIOUS DISEASES

Response to combination antiretroviral therapy: variation by age

(2009)   AIDS

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

(2009) Jeffrey L Lennox et al.   LANCET

The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy

(2008) CA Sabin et al.   HIV MEDICINE